|Videos|February 17, 2016
- Gastrointestinal Cancers: mCRC (Issue 7)
- Volume 1
- Issue 7
Dr. Manish A. Shah on BBI608 in the Treatment Paradigm for Gastrointestinal Cancers
Author(s)Manish A. Shah, MD
Shah says as more treatments become available, oncologists need to consider the order in which they give treatments to patients with gastric and gastroesophageal junction cancer.
Manish A. Shah, MD, medical oncologist, Bartlett Associate Professor of GI Oncology, Weill Cornell Medical Center at NewYork-Presbyterian Hospital, discusses how BBI608 might fit into the treatment paradigm for gastric and gastroesophageal junction cancer. Shah says as more treatments become available, oncologists need to consider the order in which they give patients treatments. He adds that not all gastric cancers are the same, so identifying which cancers would be best treated by a PD-1 inhibitor and which would be best treated by a stem cell inhibitor is crucial.
Articles in this issue
almost 10 years ago
Neoadjuvant Therapy Continues to Evolve for Pancreatic Canceralmost 10 years ago
ERCC1 Expression Falls Short as Chemo Biomarker in mCRCalmost 10 years ago
Panitumumab Boosts Overall Survival in Chemorefractory mCRCalmost 10 years ago
Two Options Allows for Treatment Tailoring in Refractory CRCalmost 10 years ago
FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRCRelated Content
Advertisement
